drugset / Trial / NCT05513612
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Outcome
Outcome not reported
Stopped: “The study is not initiated and we want it to be withdrawn.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous CAR-T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |